Cxbladder评估及对不典型细胞学和可疑膀胱镜检查的判定
该研究为回顾性汇总分析,纳入美国、澳大利亚和新西兰三项前瞻性Cxbladder临床试验及一项真实世界研究的1784例连续前瞻性招募的血尿或既往诊断为尿路上皮癌患者,其中852例同时有局部细胞学和Cxbladder结果,153例细胞学不典型,14例同时有细胞学不典型和膀胱镜检查可疑。Cxbladder排除35%的患者,阴性预测值为97%(95%CI 94-98%),细胞学为93%(95%CI 91-94%);Cxbladder漏诊8.5%的肿瘤,细胞学漏诊63%。153例细胞学不典型中26例(17%)诊断为尿路上皮癌,Cxbladder正确判定所有 these 患者,包括同时有细胞学不典型和膀胱镜检查可疑者。
要点
- Cxbladder排除35%的患者,阴性预测值97%,细胞学阴性预测值93%。
- Cxbladder漏诊8.5%的肿瘤,细胞学漏诊63%。
- 153例细胞学不典型中26例(17%)诊断为尿路上皮癌,Cxbladder正确判定所有 these 患者。
核心结论
- Cxbladder正确判定了细胞学不典型和膀胱镜检查可疑患者中所有诊断为尿路上皮癌的病例,并在准确识别无尿路上皮癌患者方面优于细胞学。
研究设计与样本
- 回顾性分析,汇总三项前瞻性Cxbladder临床试验和一项真实世界临床研究的数据;医师对Cxbladder结果设盲,Cxbladder提供者对临床结果设盲;分析美国、澳大利亚和新西兰的多种泌尿外科实践;共1784例连续前瞻性招募的血尿或既往诊断为尿路上皮癌患者,其中852例同时有局部细胞学和Cxbladder结果;153例细胞学不典型,14例同时有细胞学不典型和膀胱镜检查可疑。
主要发现
- Cxbladder排除35%的患者,阴性预测值97%(95%CI 94-98%),细胞学阴性预测值93%(95%CI 91-94%)。
- Cxbladder漏诊8.5%的肿瘤,细胞学漏诊63%的肿瘤。
- 153例细胞学不典型中26例(17%)诊断为尿路上皮癌,Cxbladder正确判定所有 these 患者,包括同时有细胞学不典型和膀胱镜检查可疑者。
- 同时有细胞学不典型和膀胱镜检查可疑的患者发生率低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). OBJECTIVE: To evaluate the performance of Cxbladder and urine cytology, and Cxbladder's adjudication of atypical cytology and equivocal cystoscopy. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective analysis of pooled data from three prospective Cxbladder clinical trials and one real-world clinical study. Physicians were blinded to Cxbladder results, and Cxbladder providers were blinded to clinical results. This study analyzed diverse urology practices in the USA, Australia, and New Zealand. A total of 1784 consecutive, prospectively recruited patients with hematuria or previously diagnosed UC provided 852 samples with both local cytology and Cxbladder results; 153 had atypical cytologies and 14 had both atypical cytology and equivocal cystoscopy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Negative predictive value (NPV) and proportion of tumors missed for Cxbladder and local cytology, and evaluation of Cxbladder for adjudicating atypical cytology and equivocal cystoscopy. RESULTS AND LIMITATIONS: Cxbladder ruled out 35% of patients and NPV 97% (95% confidence interval [CI] 94-98%) compared with 93% (95% CI 91-94%) for cytology; Cxbladder missed 8.5% and cytology missed 63% of tumors. UC was diagnosed in 26/153 cases of atypical cytology (17%). Cxbladder correctly adjudicated all these patients including those with both atypical cytology and equivocal cystoscopy; these patients had a positive Cxbladder result and were diagnosed with UC by pathology. The incidence of patients with both atypical cytology and equivocal cystoscopy is low. CONCLUSIONS: Cxbladder correctly adjudicated all patients diagnosed with UC among those with atypical cytology and equivocal cystoscopy, and outperformed cytology for accurately identifying patients who do not have UC. PATIENT SUMMARY: Cxbladder accurately rules out patients who do not have cancer, and adjudicates cytology and cystoscopy with inconclusive results, minimizing the need for patients to undergo further unnecessary tests and procedures.
引用
- Konety B, Shore N, Kader AK, et al. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019. PMID: 31103391. doi:10.1016/j.eururo.2019.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。